Loading
Fungal Infections and Studies / Nail Diseases and Treatments · Journal article
Mycoses · September 1, 2026
A consensus or society position rather than new primary data.
This is a narrative review of emerging and uncommon fungal pathogens in Asia, summarizing epidemiological trends, diagnostic approaches, antifungal susceptibility patterns, and treatment strategies without reporting primary trial or comparative outcome data. It serves as a clinical knowledge synthesis intended to enhance awareness and inform evidence-based practice rather than as a source of quantified clinical evidence.
Journal article. Immunocompromised individuals in Asia affected by emerging and uncommon fungal pathogens. Asia.
Candida and Aspergillus remain leading causes of invasive fungal disease in Asia, but uncommon yeasts and rare moulds including Mucorales, Basidiomycetes, non-marneffei Talaromyces, Oomycetes and Emergomyces show increasing clinical importance Many emerging pathogens demonstrate intrinsic or acquired antifungal resistance, presenting therapeutic challenges Organisms primarily affect immunocompromised individuals and cause fungaemia, invasive pulmonary disease, cutaneous and disseminated infections
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians and mycologists should maintain heightened awareness of emerging fungal pathogens in Asia, employ molecular diagnostics for identification, perform susceptibility testing to guide therapy selection, and consider prompt surgical intervention where indicated. The review informs diagnostic and therapeutic strategy but does not provide evidence-based outcome comparisons to change current practice.
A narrative review synthesizing epidemiology, diagnostics, and management of emerging fungal pathogens in Asia without reporting original trial data or new clinical outcomes.
As stated by the source record.
Clinicians and mycologists should maintain heightened awareness of emerging fungal pathogens in Asia, employ molecular diagnostics for identification, perform susceptibility testing to guide therapy selection, and consider prompt surgical intervention where indicated. The review informs diagnostic and therapeutic strategy but does not provide evidence-based outcome comparisons to change current practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Fungal infections in Asia are influenced by warm, humid climates, high population density and expanding healthcare systems, which together facilitate the emergence, transmission and detection of both common and rare pathogens. While Candida and Aspergillus species remain the leading causes of invasive fungal disease, increasing attention has focused on uncommon yeasts and rare moulds, many of which show intrinsic or acquired antifungal resistance. Advances in molecular diagnostics and susceptibility testing have improved identification of emerging pathogens, including uncommon Candida species and rare moulds such as Mucorales, filamentous Basidiomycetes, non-marneffei Talaromyces, Oomycetes and thermally dimorphic fungi like Emergomyces. These organisms primarily affect immunocompromised individuals and present significant diagnostic and therapeutic challenges due to identification difficulties, variable susceptibility patterns and limited clinical experience. Clinical presentations range from fungaemia and invasive pulmonary disease to cutaneous and disseminated infections. Treatment is guided by pathogen and susceptibility profiles, commonly involving echinocandins, amphotericin B and azoles. In some cases, particularly infections caused by Oomycetes and Mucorales, prompt surgical intervention is essential. This review provides a comprehensive overview of current epidemiological trends, risk factors, clinical features, antifungal susceptibility patterns and treatment outcomes associated with rare and emerging fungal pathogens in Asia. By highlighting these increasingly recognized infections, it aims to enhance awareness among clinicians and mycologists, promote evidence-based diagnostic and therapeutic approaches and inform future research addressing this evolving and clinically significant public health challenge.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.